Microperimetry Changes in Retinal Function in Macular Disorders
A legfontosabb adatok
- Ki végzi
- University of Nottingham
- Hol
- Nottingham (Egyesült Királyság)A helyszín megnézése
- Azonosító
- Állapot
- Csak meghívásos
- Résztvevők
- 200 fő, tervezett
- Kezdés
- 2025. ápr. 4.
- Tervezett befejezés
- 2026. aug. 30.
- A vizsgálat típusa
- Megfigyeléses, 4 csoport
- A vizsgált kezelések
- MAIA Microperimetry
- Microperimetry
- Visual Acuity Measurement (logMAR)
- OCT-A
- A regiszteradat frissítve
- 2025. szeptember 12.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
A vizsgálat olyan felnőtteket keres, akiknek száraz időskori makuladegenerációja (geográfiai atrófia) vagy cukorbetegsége enyhe vagy közepes szemfenéki érintettséggel van, valamint egészséges, szembetegség nélküli felnőtteket összehasonlító csoportnak.
- Életkor
- 21 év felett; az egészséges összehasonlító csoportnál felső korhatár nincs megadva.
- Nem
- Minden nem részt vehet.
- A betegség stádiuma
- Geográfiai atrófia (száraz AMD), vagy cukorbetegség retinopátia nélkül, vagy minimális-közepes nem proliferatív diabéteszes retinopátia, OCT-n látható makulaödémával vagy anélkül. Az egészséges kontrollnak nincs retina-, látóideg- vagy glaukómabetegsége, és nem cukorbeteg.
- Korábbi kezelés
- Nem vehet részt, aki az elmúlt 6 hónapban anti-VEGF vagy szteroid injekciót kapott a szemébe, vagy makulalézer-kezelésen esett át.
- Biomarker vagy leletérték
- Látásélesség a betegeknél LogMAR 0.0 és 1.2 között; az egészséges kontrolloknál LogMAR 0.2 alatt.
A részvétel fő kizáró okai
- Közepes vagy súlyos szürkehályog (2-es fokozat felett) vagy más, a szemvizsgálatot akadályozó homály
- Anti-VEGF vagy szteroid injekció a szembe az elmúlt 6 hónapban, vagy makulalézer
- Aktív érrendszeri esemény bármelyik szemben
- Nem tud vagy nem akar beleegyező nyilatkozatot adni
- Nem olvas folyékonyan angolul
A regiszter feltételei, szó szerint
Mind a 23 feltétel megnézéseKevesebb
Ki vehet részt
- Adult age above 21 years old
- Signed informed consent
- Visual acuity Log MAR 0.0 to 1.2
- Patients diagnosed with:; Geographic atrophy (AMD); Diabetic without retinopathy, and minimal to moderate non-proliferative diabetic retinopathy (NPDR) with or without presence of macular oedema on optical coherence tomography (OCT)
- Control group of age matched participants without any retinal disease, glaucoma or optic nerve disease in either eye Patients willing to attend follow-up MP examinations. (This does not apply to normal controls who only require one attendance)
Ki nem vehet részt
- Previous treatments in the eye with intravitreal therapies of anti-VEGFs or steroids within the previous 6 months, or macular laser photocoagulation
- Previous treatments in the particular eye with intravitreal therapies of anti-VEGFs or steroids within the previous 6 months, or macular laser photocoagulation
- Active/previous vascular event in either eye e.g. retinal arterial or vein occlusion, ischaemic optic neuropathy, or glaucoma
- Normal controls will include persons who are not diabetic, and do not have glaucoma, any retinal or optic nerve disease
- Persons with diabetes
- Adult age above 21 years old. No upper age limit
- Moderate to severe cataract (over grade 2) or other cause of opaque optical media that will preclude adequate fundoscopy or MP assessment
- Active vascular event in either eye any examination time
- Participants who are unable/unwilling to provide consent
- Participants who are unable to read English fluently
- Normal Controls Inclusion Criteria
- Signed informed consent
- Visual acuity LogMAR <0.2
- Controls should be willing to attend once only
- Moderate to severe cataract (over grade 2) or other cause of opaque optical media
- Participants who are unable to read English fluently
- Participants who are unable/unwilling to provide consent
Egyéb feltételek
- Patients
Helyszínek itt: Egyesült Királyság
- Nottingham University Hospitals NHS TrustNottingham, Egyesült KirályságCsak meghívásos
A vizsgálatról
Mit akar kideríteni a vizsgálat
The purpose of this study is to measure precisely how sensitive the central part of the retina - the light-sensitive film at the back of the eye, is to light. We will use a special device called the Macular Integrity Assessment (MAIA) microperimetry (MP) system to achieve this, particularly for individuals with specific retinal conditions. The macula (with the fovea at its very centre) is the part of the retina responsible for our fine detailed vision, colour vision, and maintaining steady gaze on objects (called 'fixation'). Diseases that affect the macula lead to difficulties in seeing clearly.
A teljes eredeti leírásKevesebb
Macular sensitivity refers to how responsive the macula is to light, including the ability to read and focus on objects. This also determines how well the eye can maintain a steady gaze on objects of interest ('fixation'). While standard eye tests primarily measure vision in the fovea, measuring sensitivity across the wider macula would provide a more complete picture of visual function. Furthermore, we believe that macular sensitivity changes are often one of the earliest signs of retinal diseases, before a person experiences blurry vision. Currently, MP is not used routinely in UK NHS clinical practice.
The commonest retinal diseases are age-related macular degeneration (AMD) and diabetic retinopathy (DR). There are 2 types of AMD: dry and wet.
* Dry AMD is a condition that affects the central part of the retina (the macula) and can lead to gradual vision loss as people age. This is due to wearing out and loss of the slight sensitive cells in the macula that can make it harder to see fine details, such as reading or recognizing faces. * Diabetic retinopathy means that diabetes has affected the blood vessels in the retina. In the early stages, the affected blood vessels do not leak. However, progression results in leakage of the blood vessels in the retina, leading to retinal swelling (called diabetic macular oedema [DMO]). Eyes with DMO function less well compared to when there is no swelling.
It is important to investigate these selected common conditions further, in order to find ways of detecting changes earlier, before the patient notices any abnormalities. Such earlier detection may result in better understanding and treatments in the future.
The main goal of this research is to measure macular sensitivity and ability to maintain a steady gaze on specific objects or points in patients with these macular disorders using the MAIA device. These measurements will be compared to changes in the structure of the macula, obtained using advanced imaging techniques like optical coherence tomography (OCT) and OCT angiography (OCTA), which are routinely used in standard clinical practice.
This study will form part of a research/educational thesis, and provide additional data to complement previous research on the topic.
Participants (after consent) will have MP done. In addition, we will assess information from their eye clinic records, including images and scans of the back of the eyes (OCT and OCTA). No treatment interventions are planned as part of this study. Participants standard of care will not be affected.
Participants will have tests done at baseline, and repeated at 6 and 12 months. In addition, we will invite a group of normal controls (i.e. persons who do not have any diseases of the back of their eyes) for comparison. This will ensure validity of our findings. The normal controls will attend only once (at baseline). After consent is obtained, these healthy participants will have MP, and imaging of the macula with OCT.
A vizsgálat 4 csoportja
- Participants with dry AMD (including geographic atrophy [GA])
Participants with dry AMD including GA. MP will be performed in 2 different modalities, a full staircase threshold stimuli projection, and a simplified stimuli projection of 4 fixed levels of stimuli intensity. OCT and OCT-A will be done with the Topcon Triton. Best habitual corrected distance VA (logMAR) will be recorded.
Kezelés: MAIA Microperimetry, Microperimetry, Visual Acuity Measurement (logMAR) és OCT-A
- Persons with diabetes without diabetic retinopathy
Participants with diabetes without diabetic retinopathy. MP will be performed in 2 different modalities, a full staircase threshold stimuli projection, and a simplified stimuli projection of 4 fixed levels of stimuli intensity. OCT and OCT-A will be done with the Topcon Triton. Best habitual corrected distance VA (logMAR) will be recorded.
Kezelés: MAIA Microperimetry, Microperimetry, Visual Acuity Measurement (logMAR) és OCT-A
- Participants with diabetes with mild to moderate diabetic retinopathy (i.e. non-proliferative DR)..
Participants with diabetes with mild to moderate diabetic retinopathy. MP will be performed in 2 different modalities, a full staircase threshold stimuli projection, and a simplified stimuli projection of 4 fixed levels of stimuli intensity. OCT and OCT-A will be done with the Topcon Triton. Best habitual corrected distance VA (logMAR) will be recorded.
Kezelés: MAIA Microperimetry, Microperimetry, Visual Acuity Measurement (logMAR) és OCT-A
- Normal (healthy) controls
Normal controls will include persons who are not diabetic, and do not have glaucoma, any retinal or optic nerve disease. MP will be performed in 2 different modalities, a full staircase threshold stimuli projection, and a simplified stimuli projection of 4 fixed levels of stimuli intensity. OCT and OCT-A will be done with the Topcon Triton. Best habitual corrected distance VA (logMAR) will be recorded.
Kezelés: MAIA Microperimetry, Microperimetry, Visual Acuity Measurement (logMAR) és OCT-A
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- An Investigation of Microperimetry for Monitoring Retinal Function in Selected Macular Disorders
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 12.
- A regiszteradat frissítve
- 2025. szeptember 12.